Search company, investor...


Founded Year



Acquired | Acquired

Total Raised






About Cellomics

Cellomics offers systems for High Content Screening (HCS) and High Content Analysis (HCA) to drug discovery and systems biology researchers. Cellomics, Thermo Scientific Cellomics family of products offers a total platform, comprising automated imaging instrumentation, BioApplication image analysis software and high content informatics, coupled together with reagents, laboratory automation and services to provide the life science researcher with possible "time-to-decision". The company's products are being applied today in all aspects of the drug discovery process from target id and validation through screening and ADME/Tox to pre-clinical, as well as academic research. nnn

Headquarters Location

100 Technology Drive

Pittsburgh, Pennsylvania, 15219,

United States


Missing: Cellomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cellomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cellomics Patents

Cellomics has filed 28 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Artificial intelligence
  • Artificial neural networks
patents chart

Application Date

Grant Date


Related Topics




Microscopy, Spectroscopy, Molecular biology, Cell imaging, Cell biology


Application Date


Grant Date



Related Topics

Microscopy, Spectroscopy, Molecular biology, Cell imaging, Cell biology



Latest Cellomics News

High-end Cellomics Market Worth USD 536.9 Mn by 2031 | Get Insights FMI

Dec 5, 2022

| Get Insights FMI According to a recent Future Market Insights (FMI) industry analysis, the demand in the  high-end cellomics market  is expected to top US$ 288.8 Mn in 2021, growing at a CAGR of 6.4% during the forecast period 2021-2031. High-end cellomics is a process that is utilized in drug discovery and biological research to identify substances such as small molecules, RNAi or peptides which alter the phenotype of a cell in a wanted manner. The global high-end cellomics market is primarily driven by increasing technological advancement in imaging solutions. Technological advancements such as the usage of polarization methods, multicolored fluorescence-based reagents, automated imaging technology, and flow cytometry are also anticipated to boost the market growth further. Increasing investment in research and development in cellular science of novel molecules by private and government organizations, technological advancement in imaging solutions, and advantages related to these innovations such as improved scope for pplication in gene documentation & neonatal development learning will drive the high-end cellomics market. Key Takeaways from High-end Cellomics Market Study The global high-end cellomics market is expected to reach US$ 536.9 Mn by 2031. By application, drug discovery accounted for 55.5% of overall sales in 2021 and is expected to continue to grow at the same trend during the forecast period. By end-users, pharmaceutical and biotechnology companies will account for the largest share of 51.8% during the forecast period. By region, North America held the largest share of 32.7% of the global high-end cellomics market. By country, the U.S. is the most lucrative market in the global high-end cellomics market with US$ 81.7 Mn revenue in 2021. Request Sample PDF Brochure: Who is Winning? Some of the leading manufacturers of high-end cellomics are focusing on product approvals and launch strategies for global expansion objectives, thereby, enhancing their market presence. The leading key players are focusing on strategic alliance to expand the product offerings. Yokogawa Electronic Corporation in December 2020, agreed with InSphero AG to jointly promote the use of Yokogawa’s high-end cellomics systems for drug discovery research which actively involves the use of 3D in vitro models. The key market players covered by FMI include PerkinElmer, Inc., ThermoFisher Scientific, Inc., Molecular Devices LLC (part of Danaher Corporation) and Yokogawa Electric Corporation. About the Healthcare Division at Future Market Insights Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here High-end Cellomics Market by Category Application: About Future Market Insights, Inc. Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through  MarketNgage , the market intelligence engine from Future Market Insights. Sign Up  for a 7 day free trial! Contact Us:

Cellomics Frequently Asked Questions (FAQ)

  • When was Cellomics founded?

    Cellomics was founded in 1996.

  • Where is Cellomics's headquarters?

    Cellomics's headquarters is located at 100 Technology Drive, Pittsburgh.

  • What is Cellomics's latest funding round?

    Cellomics's latest funding round is Acquired.

  • How much did Cellomics raise?

    Cellomics raised a total of $75.11M.

  • Who are the investors of Cellomics?

    Investors of Cellomics include Thermo Fisher Scientific, InterWest Partners, Axiom Venture Partners, Oxford Bioscience Partners, Vector Fund Management and 12 more.

  • Who are Cellomics's competitors?

    Competitors of Cellomics include Gentronix Limited, BioDiscovery, Visiopharm, Fluxion Biosciences, Echelon Biosciences, Prosarix, Guava Technologies, Sword Diagnostics, Aushon BioSystems, CytoBioscience and 28 more.

Compare Cellomics to Competitors

Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

Fluxion Biosciences Logo
Fluxion Biosciences

Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.

Genomic Solutions

The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.

AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.


PlexPress is a life science company doing work in gene expression analysis technology to advance biological science, drug discovery, crop science and diagnostics. PlexPress seeks to rapidly provide reliable information at low cost. Its products simultaneously measure multiple genes from multiple samples. PlexPress operates from Los Altos, California and Helsinki, Finland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.